• Vaccine Name: BBIBP-CorV
• Target Pathogen: SARS-CoV-2
• Target Disease: COVID-19
• Manufacturer: Beijing Institute of Biological Products, Sinopharm
• Vaccine Ontology ID: VO_0005167
• Type: Inactivated or "killed" vaccine
• Status: Clinical trial
• Host Species for Licensed Use: Human
• Antigen: whole virus
• Immunization Route: Intramuscular injection (i.m.)
• Description: An inactivated whole virus vaccine produced in Vero cells.

Macaque Response

• Vaccination Protocol: All macaques were immunized twice on days 0 (D0) and 14 (D14). The placebo group was intramuscularly administered physiological saline, and the two experimental groups were intramuscularly injected with low-dose (2 μg/dose) or high-dose (8 μg/dose) BBIBP-CorV. (Wang et al., 2020)
• Immune Response: Before virus challenge at D24, the geometric mean titer of neutralizing antibodies in the low-dose and high-dose groups reached 215 and 256, respectively. (Wang et al., 2020)
• Challenge Protocol: At D24 (10 days after the second immunization), all macaques were intratracheally challenged with l06 TCID50 of SARS-CoV-2 per monkey under anesthesia. (Wang et al., 2020)
• Efficacy: All placebo macaques showed and maintained a high viral load during the whole evaluation period after virus challenge by both throat and anal swabs. In contrast, the viral load in the throat swabs of the low-dose group peaked (5.33 log10copies/mL) at 5 dpi and then decreased to 1.12 log10copies/mL at 7 dpi, which was significantly lower than that of the placebo group. Moreover, no viral load was detected in the anal swabs of two (out of four) macaques in the high-dose group. (Wang et al., 2020) No macaques in the low-dose and high-dose groups had a detectable viral load in any lung lobe, which was significantly different from the results in the placebo group. Furthermore, all macaques that received vaccination showed normal lung with focal mild histopathological changes in few lobes, demonstrating the BBIBP-CorV vaccination could efficiently block the infection of SARS-CoV-2 and COVID-19 disease in monkey. At 7 dpi, the macaques treated with placebo produced low-level NAb with a titer of 1:16, whereas the NAb levels of the vaccinated macaques were highest at 1:2,048 (average 1:860) in the high-dose group and 1:1,024 in the low-dose group (average 1:512). Taken together, all these results demonstrated that both low-dose and high-dose BBIBP-CorV conferred highly efficient protection against SARS-CoV-2 in macaques without observed antibody-dependent enhancement of infection. (Wang et al., 2020)